{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T10:48:24Z","timestamp":1790419704661,"version":"4.1.0"},"reference-count":39,"publisher":"Deutscher Arzte-Verlag GmbH","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"DOI":"10.3238\/arztebl.m2023.0287","type":"journal-article","created":{"date-parts":[[2024,4,9]],"date-time":"2024-04-09T13:59:28Z","timestamp":1712671168000},"source":"Crossref","is-referenced-by-count":16,"title":["The clinical features of hereditary alpha-tryptasemia"],"prefix":"10.3238","author":[{"given":"Dagmar","family":"von Bubnoff","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Koch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hannah","family":"Stocker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ralf J.","family":"Ludwig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Friederike","family":"Wortmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikolas","family":"von Bubnoff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"11437","published-online":{"date-parts":[[2024,4,19]]},"reference":[{"key":"10.3238\/arztebl.m2023.0287_ref1","doi-asserted-by":"crossref","unstructured":"Lyons JJ, Yu X, Hughes JD, et al.: Elevated basal serum tryptase identifies a multisystem disorder associated with increased TPSAB1 copy number. Nat Genet 2016; 48: 1564–9.","DOI":"10.1038\/ng.3696"},{"key":"10.3238\/arztebl.m2023.0287_ref2","doi-asserted-by":"crossref","unstructured":"Valent P, Sperr WR, Sotlar K, et al.: The serum tryptase test: an emerging robust biomarker in clinical hematology. Expert Rev Hematol 2014; 7: 683–90.","DOI":"10.1586\/17474086.2014.955008"},{"key":"10.3238\/arztebl.m2023.0287_ref3","doi-asserted-by":"crossref","unstructured":"Stoevesandt J, Sturm GJ, Bonadonna P, Oude Elberink JNG, Trautmann A: Risk factors and indicators of severe systemic insect sting reactions. Allergy 2020; 75: 535–45.","DOI":"10.1111\/all.13945"},{"key":"10.3238\/arztebl.m2023.0287_ref4","doi-asserted-by":"crossref","unstructured":"Schwartz LB: Diagnostic value of tryptase in anaphylaxis and mastocytosis. Immunol Allergy Clin North Am 2006; 26: 451–63.","DOI":"10.1016\/j.iac.2006.05.010"},{"key":"10.3238\/arztebl.m2023.0287_ref5","doi-asserted-by":"crossref","unstructured":"Valent P, Akin C, Sperr WR, et al.: New Insights into the pathogenesis of mastocytosis: emerging concepts in diagnosis and therapy. Annu Rev Pathol 2023; 18: 361–86.","DOI":"10.1146\/annurev-pathmechdis-031521-042618"},{"key":"10.3238\/arztebl.m2023.0287_ref6","doi-asserted-by":"crossref","unstructured":"Glover SC, Carter MC, Korosec P, et al.: Clinical relevance of inherited genetic differences in human tryptases: hereditary alpha-tryptasemia and beyond. Ann Allergy Asthma Immunol 2021; 127: 638–47.","DOI":"10.1016\/j.anai.2021.08.009"},{"key":"10.3238\/arztebl.m2023.0287_ref7","doi-asserted-by":"crossref","unstructured":"Luskin KT, White AA, Lyons JJ: The genetic basis and clinical impact of hereditary alpha-tryptasemia. J Allergy Clin Immunol Pract 2021; 9: 2235–42.","DOI":"10.1016\/j.jaip.2021.03.005"},{"key":"10.3238\/arztebl.m2023.0287_ref8","doi-asserted-by":"crossref","unstructured":"Lyons JJ: Hereditary alpha tryptasemia: genotyping and associated clinical features. Immunol Allergy Clin North Am 2018; 38: 483–95.","DOI":"10.1016\/j.iac.2018.04.003"},{"key":"10.3238\/arztebl.m2023.0287_ref9","doi-asserted-by":"crossref","unstructured":"Greiner G, Sprinzl B, Gorska A, et al.: Hereditary alpha tryptasemia is a valid genetic biomarker for severe mediator-related symptoms in mastocytosis. Blood 2021; 137: 238–47.","DOI":"10.1182\/blood.2020006157"},{"key":"10.3238\/arztebl.m2023.0287_ref10","doi-asserted-by":"crossref","unstructured":"Lyons JJ, Chovanec J, O‘Connell MP, et al.: Heritable risk for severe anaphylaxis associated with increased alpha-tryptase-encoding germline copy number at TPSAB1. J Allergy Clin Immunol 2021; 147: 622–32.","DOI":"10.1016\/j.jaci.2020.06.035"},{"key":"10.3238\/arztebl.m2023.0287_ref11","doi-asserted-by":"crossref","unstructured":"O‘Connell MP, Lyons JJ: Hymenoptera venom-induced anaphylaxis and hereditary alpha-tryptasemia. Curr Opin Allergy Clin Immunol 2020; 20: 431–7.","DOI":"10.1097\/ACI.0000000000000678"},{"key":"10.3238\/arztebl.m2023.0287_ref12","doi-asserted-by":"crossref","unstructured":"Chovanec J, Tunc I, Hughes J, et al.: Genetically determining individualized clinical reference ranges for the biomarker tryptase can limit unnecessary procedures and unmask myeloid neoplasms. Blood Adv 2023; 7:1796–810.","DOI":"10.1182\/bloodadvances.2022007936"},{"key":"10.3238\/arztebl.m2023.0287_ref13","doi-asserted-by":"crossref","unstructured":"Gonzalez-Quintela A, Vizcaino L, Gude F, et al.: Factors influencing serum total tryptase concentrations in a general adult population. Clin Chem Lab Med 2010; 48: 701–6.","DOI":"10.1515\/CCLM.2010.124"},{"key":"10.3238\/arztebl.m2023.0287_ref14","doi-asserted-by":"crossref","unstructured":"Fellinger C, Hemmer W, Wohrl S, Sesztak-Greinecker G, Jarisch R, Wantke F: Clinical characteristics and risk profile of patients with elevated baseline serum tryptase. Allergol Immunopathol (Madr) 2014; 42: 544–52.","DOI":"10.1016\/j.aller.2014.05.002"},{"key":"10.3238\/arztebl.m2023.0287_ref15","doi-asserted-by":"crossref","unstructured":"Robey RC, Wilcock A, Bonin H, et al.: Hereditary alpha-tryptasemia: UK prevalence and variability in disease expression. J Allergy Clin Immunol Pract 2020; 8: 3549–56.","DOI":"10.1016\/j.jaip.2020.05.057"},{"key":"10.3238\/arztebl.m2023.0287_ref16","doi-asserted-by":"crossref","unstructured":"Wu R, Lyons JJ: Hereditary alpha-tryptasemia: a commonly inherited modifier of anaphylaxis. Curr Allergy Asthma Rep 2021; 21: 33.","DOI":"10.1007\/s11882-021-01010-1"},{"key":"10.3238\/arztebl.m2023.0287_ref17","doi-asserted-by":"crossref","unstructured":"Le QT, Lyons JJ, Naranjo AN, et al.: Impact of naturally forming human alpha\/beta-tryptase heterotetramers in the pathogenesis of hereditary alpha-tryptasemia. J Exp Med 2019; 216: 2348–61.","DOI":"10.1084\/jem.20190701"},{"key":"10.3238\/arztebl.m2023.0287_ref18","doi-asserted-by":"crossref","unstructured":"Trivedi NN, Tamraz B, Chu C, Kwok PY, Caughey GH: Human subjects are protected from mast cell tryptase deficiency despite frequent inheritance of loss-of-function mutations. J Allergy Clin Immunol 2009; 124: 1099–105.e1–4.","DOI":"10.1016\/j.jaci.2009.07.026"},{"key":"10.3238\/arztebl.m2023.0287_ref19","doi-asserted-by":"crossref","unstructured":"Polivka L, Madrange M, Bulai-Livideanu C, et al.: Pathophysiologic implications of elevated prevalence of hereditary alpha-tryptasemia in all mastocytosis subtypes. J Allergy Clin Immunol 2024; 153: 349–53.","DOI":"10.1016\/j.jaci.2023.08.015"},{"key":"10.3238\/arztebl.m2023.0287_ref20","doi-asserted-by":"crossref","unstructured":"Waters AM, Park HJ, Weskamp AL, et al.: Elevated basal serum tryptase: disease distribution and variability in a regional health system. J Allergy Clin Immunol Pract 2022; 10: 2424–35.e5.","DOI":"10.1016\/j.jaip.2021.12.031"},{"key":"10.3238\/arztebl.m2023.0287_ref21","doi-asserted-by":"crossref","unstructured":"Sperr WR, El-Samahi A, Kundi M, et al.: Elevated tryptase levels selectively cluster in myeloid neoplasms: a novel diagnostic approach and screen marker in clinical haematology. Eur J Clin Invest 2009; 39: 914–23.","DOI":"10.1111\/j.1365-2362.2009.02184.x"},{"key":"10.3238\/arztebl.m2023.0287_ref22","doi-asserted-by":"crossref","unstructured":"Sperr WR, Hauswirth AW, Valent P: Tryptase a novel biochemical marker of acute myeloid leukemia. Leuk Lymphoma 2002; 43: 2257–61.","DOI":"10.1080\/1042819021000039965"},{"key":"10.3238\/arztebl.m2023.0287_ref23","doi-asserted-by":"crossref","unstructured":"Klion AD, Noel P, Akin C, et al.: Elevated serum tryptase levels identify a subset of patients with a myeloproliferative variant of idiopathic hypereosinophilic syndrome associated with tissue fibrosis, poor prognosis, and imatinib responsiveness. Blood 2003; 101: 4660–6.","DOI":"10.1182\/blood-2003-01-0006"},{"key":"10.3238\/arztebl.m2023.0287_ref24","doi-asserted-by":"crossref","unstructured":"Guo Y, Wu Q, Ni B, et al.: Tryptase is a candidate autoantigen in rheumatoid arthritis. Immunology 2014; 142: 67–77.","DOI":"10.1111\/imm.12197"},{"key":"10.3238\/arztebl.m2023.0287_ref25","doi-asserted-by":"crossref","unstructured":"Kutty GR, Downs-Kelly E, Crispin HT, Peterson KA: Elevated tryptase in EoE is an independent phenomenon associated with extra-esophageal symptoms. Dig Dis Sci 2019; 64: 152–7.","DOI":"10.1007\/s10620-018-5298-7"},{"key":"10.3238\/arztebl.m2023.0287_ref26","doi-asserted-by":"crossref","unstructured":"Afrin LB, Pohlau D, Raithel M, et al.: Mast cell activation disease: an underappreciated cause of neurologic and psychiatric symptoms and diseases. Brain Behav Immun 2015; 50: 314–21.","DOI":"10.1016\/j.bbi.2015.07.002"},{"key":"10.3238\/arztebl.m2023.0287_ref27","doi-asserted-by":"crossref","unstructured":"Theoharides TC: COVID-19, pulmonary mast cells, cytokine storms, and beneficial actions of luteolin. Biofactors 2020; 46: 306–8.","DOI":"10.1002\/biof.1633"},{"key":"10.3238\/arztebl.m2023.0287_ref28","doi-asserted-by":"crossref","unstructured":"Hasler WL, Grabauskas G, Singh P, Owyang C: Mast cell mediation of visceral sensation and permeability in irritable bowel syndrome. Neurogastroenterol Motil 2022; 34: e14339.","DOI":"10.1111\/nmo.14339"},{"key":"10.3238\/arztebl.m2023.0287_ref29","doi-asserted-by":"crossref","unstructured":"Giannetti MP, Weller E, Bormans C, Novak P, Hamilton MJ, Castells M: Hereditary alpha-tryptasemia in 101 patients with mast cell activation-related symptomatology including anaphylaxis. Ann Allergy Asthma Immunol 2021; 126: 655–60.","DOI":"10.1016\/j.anai.2021.01.016"},{"key":"10.3238\/arztebl.m2023.0287_ref30","doi-asserted-by":"crossref","unstructured":"Konnikova L, Robinson TO, Owings AH, et al.: Small intestinal immunopathology and GI-associated antibody formation in hereditary alpha-tryptasemia. J Allergy Clin Immunol 2021; 148: 813–21.e7.","DOI":"10.1016\/j.jaci.2021.04.004"},{"key":"10.3238\/arztebl.m2023.0287_ref31","doi-asserted-by":"crossref","unstructured":"Black CJ, Ford AC: Global burden of irritable bowel syndrome: trends, predictions and risk factors. Nat Rev Gastroenterol Hepatol 2020; 17: 473–86.","DOI":"10.1038\/s41575-020-0286-8"},{"key":"10.3238\/arztebl.m2023.0287_ref32","doi-asserted-by":"crossref","unstructured":"Selb J, Rijavec M, Erzen R, et al.: Routine KIT p.D816V screening identifies clonal mast cell disease in patients with Hymenoptera allergy regularly missed using baseline tryptase levels alone. J Allergy Clin Immunol 2021; 148: 621–6.e7.","DOI":"10.1016\/j.jaci.2021.02.043"},{"key":"10.3238\/arztebl.m2023.0287_ref33","doi-asserted-by":"crossref","unstructured":"Selb J, Rijavec M, Kopac P, Lyons JJ, Korosec P: HalphaT is associated with increased risk for severe Hymenoptera venom-triggered anaphylaxis. J Allergy Clin Immunol 2023; 151: 804–5.","DOI":"10.1016\/j.jaci.2022.11.017"},{"key":"10.3238\/arztebl.m2023.0287_ref34","doi-asserted-by":"crossref","unstructured":"Cohen SS, Skovbo S, Vestergaard H, et al.: Epidemiology of systemic mastocytosis in Denmark. Br J Haematol 2014; 166: 521–8.","DOI":"10.1111\/bjh.12916"},{"key":"10.3238\/arztebl.m2023.0287_ref35","doi-asserted-by":"crossref","unstructured":"Zuberbier T, Altrichter S, Bauer S, et al.: S3 Guideline Urticaria. Part 2: Treatment of urticaria—German-language adaptation of the international S3 guideline. J Dtsch Dermatol Ges 2023; 21: 202–15.","DOI":"10.1111\/ddg.14932"},{"key":"10.3238\/arztebl.m2023.0287_ref36","doi-asserted-by":"crossref","unstructured":"Shibao C, Arzubiaga C, Roberts LJ 2nd, et al.: Hyperadrenergic postural tachycardia syndrome in mast cell activation disorders. Hypertension 2005; 45: 385–90.","DOI":"10.1161\/01.HYP.0000158259.68614.40"},{"key":"10.3238\/arztebl.m2023.0287_ref37","doi-asserted-by":"crossref","unstructured":"Mendoza Alvarez LB, Barker R, Nelson C, et al.: Clinical response to omalizumab in patients with hereditary alpha-tryptasemia. Ann Allergy Asthma Immunol 2020; 124: 99–100.e1.","DOI":"10.1016\/j.anai.2019.09.026"},{"key":"10.3238\/arztebl.m2023.0287_ref38","doi-asserted-by":"crossref","unstructured":"Blank S, Grosch J, Ollert M, Bilo MB: Precision medicine in hymenoptera venom allergy: diagnostics, biomarkers, and therapy of different endotypes and phenotypes. Front Immunol 2020; 11: 579409.","DOI":"10.3389\/fimmu.2020.579409"},{"key":"10.3238\/arztebl.m2023.0287_ref39","doi-asserted-by":"crossref","unstructured":"O‘Connell MP, Lyons JJ: Resolving the genetics of human tryptases: implications for health, disease, and clinical use as a biomarker. Curr Opin Allergy Clin Immunol 2022; 22: 143–52.","DOI":"10.1097\/ACI.0000000000000813"}],"container-title":["Deutsches \u00c4rzteblatt international"],"original-title":[],"link":[{"URL":"https:\/\/www.aerzteblatt.de\/10.3238\/arztebl.m2023.0287","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,15]],"date-time":"2024-11-15T23:24:21Z","timestamp":1731713061000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.aerzteblatt.de\/10.3238\/arztebl.m2023.0287"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,19]]},"references-count":39,"URL":"https:\/\/doi.org\/10.3238\/arztebl.m2023.0287","relation":{},"ISSN":["1866-0452"],"issn-type":[{"value":"1866-0452","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4,19]]}}}